PMID- 10499625
OWN - NLM
STAT- MEDLINE
DCOM- 19991122
LR  - 20220315
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 5
IP  - 9
DP  - 1999 Sep
TI  - Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian 
      carcinoma.
PG  - 2498-505
AB  - Transforming growth factor beta (TGF-beta) is an important family of cytokines 
      that may promote tumor growth in vivo through several mechanisms including 
      interference with antitumor T-cell immune responses, alteration of factors in the 
      stroma and matrix, and the promotion of angiogenesis. TGF-beta isotypes have been 
      detected in malignant and normal ovarian tissues. We have determined by 
      quantitative immunohistochemistry the density of TGF-beta1, TGF-beta2, and human 
      leukocyte antigen (HLA) Class I and Class II antigens on malignant cells in 
      paired primary and metastatic specimens from 10 patients with ovarian carcinoma. 
      Cryostat sections of specimens from the carcinomas and from normal ovaries of 
      three women of similar age without ovarian cancer were stained respectively with 
      specific antibodies to TGF-beta1, TGF-beta2, and HLA Class I and II antigens, and 
      with isotype-matched control antibodies. Antigen density was quantitated blindly 
      as mean absorbance on a SAMBA 4000 image analyzer. TGF-beta1 and TGF-beta2 were 
      overexpressed in both primary and metastatic tumor specimens in comparison with 
      normal ovarian tissue. No statistical correlation was found between the 
      expression of TGF-beta1 or TGF-beta2 and HLA class I or HLA class II, which 
      suggests that TGF-beta isotypes could have effects on the immune system other 
      than down-modulation of these HLA molecules. Furthermore, the lack of association 
      between levels of TGF-beta expression and the reduced expression of HLA molecules 
      could suggest that tumor cells expressing both HLA and TGF-beta may be suitable 
      targets for adaptive immunotherapy. Additional studies are necessary to determine 
      whether TGF-beta expressed by ovarian cancer cells merits evaluation as a 
      therapeutic target.
FAU - Gordinier, M E
AU  - Gordinier ME
AD  - Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer 
      Center, Houston 77030, USA.
FAU - Zhang, H Z
AU  - Zhang HZ
FAU - Patenia, R
AU  - Patenia R
FAU - Levy, L B
AU  - Levy LB
FAU - Atkinson, E N
AU  - Atkinson EN
FAU - Nash, M A
AU  - Nash MA
FAU - Katz, R L
AU  - Katz RL
FAU - Platsoucas, C D
AU  - Platsoucas CD
FAU - Freedman, R S
AU  - Freedman RS
LA  - eng
GR  - MO1-RR02558/RR/NCRR NIH HHS/United States
GR  - R01-CA64943/CA/NCI NIH HHS/United States
GR  - UO1-CA62461/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Protein Isoforms)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Aged
MH  - Female
MH  - Histocompatibility Antigens Class I/biosynthesis
MH  - Histocompatibility Antigens Class II/biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Organ Specificity
MH  - Ovarian Neoplasms/*chemistry/pathology/surgery
MH  - Photomicrography
MH  - Protein Isoforms
MH  - Staining and Labeling/methods
MH  - Transforming Growth Factor beta/*analysis
EDAT- 1999/09/28 00:00
MHDA- 1999/09/28 00:01
CRDT- 1999/09/28 00:00
PHST- 1999/09/28 00:00 [pubmed]
PHST- 1999/09/28 00:01 [medline]
PHST- 1999/09/28 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1999 Sep;5(9):2498-505.